Home | Publications | Therapeutic | Vaccines place holder
place holder place holder

Vaccines

Global Vaccine Market Outlook (2007-2010)


Publication Date   June 2007
Publisher   RNCOS
Product Type  
Pages   110
ISBN Number   not applicable
Product Code   RCS291
Ask a question about this product?

Price £795.00

approximately: $1,485 | €1,008

Summary


The report "Global Vaccine Market Outlook (2007-2010)" provides an updated view on the global vaccine industry examining and giving a detailed review of various vaccines used for disease prevention. It examines the key trends that are governing the market at present and where the vaccine market will head in the future. The report also covers the country-level analysis of the major vaccine markets worldwide and discusses major vaccine segments covering their past, present, and future trends rationally.

Key Findings

  • Growing at the rate of 16.52%, global vaccine market will reach US$ 21.05 Billion by 2010 from US$ 11.42 Billion in 2006.
  • Cancer vaccines will grow rapidly by 2010.
  • At present, pediatric vaccines occupy a higher market share but in future, the trend will shift towards the adult vaccine segment.
  • US is the largest market for vaccines in the world followed by Japan.
  • Flu vaccines have huge demand at present and all major vaccine manufacturers are to develop the vaccine.
  • Vaccines have been found to be more profitable than the generic pharmaceutical drugs but fetch less margins than branded drugs.
  • India and China are having a robust growth in their respective vaccine markets.
  • Addiction vaccines will have a growth of over 100% after their launch in 2008.
  • The global vaccine market, in its bid to reduce costs and time to market, is likely to drive the global drug discovery CRO market.

Key Issues and Facts

The research report also addresses the issues and facts that are critical to your success in the global vaccine market:

  • Evaluation of past, current and future market trends.
  • Discussion about major vaccines and their markets.
  • A detailed analysis of the major vaccines.
  • Categories of players operating in the vaccine market.
  • Profile discussion of key players in this sector.
  • Analysis of various challenges and opportunities for the industry.

Key Players

This section provides the overview, key facts, and financial information of prominent players in the global vaccine market like Sanofi-Aventis, GlaxoSmithKline (GSK) Plc, Merck & Co. Inc, Novartis and Wyeth.

Research Methodology Used

Information Sources

Information has been sourced from various credible sources like books, newspapers, trade journals and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to access to more than 3000 paid databases.

Analysis Methods

The analysis methods ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting and cause and effect analysis.

Content


  • 1. Analyst View
  • 2. Research Overview
  • 3. Vaccines - An Introduction
    • 3.1 History
    • 3.2 Vaccine Production Stages
      • 3.2.1 Cultivation
      • 3.2.2 Purification
      • 3.2.3 Quality Control
      • 3.2.4 Packaging
    • 3.3 Vaccine Approval Process
      • 3.3.1 Phase I
      • 3.3.2 Phase II
      • 3.3.3 Phase III
      • 3.3.4 Phase IV
    • 3.4 Regulatory Frameworks & Intellectual Property Rights
      • 3.4.1 Product Equals Process
      • 3.4.2 Regulatory Requirements
      • 3.4.3 Patent Protections
    • 3.5 Types of Vaccine
      • 3.5.1 Live Attenuated Vaccines
      • 3.5.2 Killed Vaccines
      • 3.5.3 Toxoid Vaccines
      • 3.5.4 Component Vaccines
      • 3.5.5 Genetically Engineered Vaccines
      • 3.5.6 DNA Vaccines
  • 4. Market Analysis
    • 4.1 Global Vaccine Market
  • 5. Industry Performance
    • 5.1 Key Geographical Markets
      • 5.1.1 US
      • 5.1.2 Europe
      • 5.1.3 Japan
      • 5.1.4 China
      • 5.1.5 India
    • 5.2 Major Vaccine Segments
      • 5.2.1 Basic Pediatrics
      • 5.2.2 Enhanced Pediatrics
      • 5.2.3 Proprietary Pediatrics
      • 5.2.4 Adult/Travel
      • 5.2.5 Therapeutics
        • 5.2.5.1 Cancer Vaccines
        • 5.2.5.2 Addiction Vaccines
      • 5.2.6 Influenza
  • 6. Major Pediatric Vaccines
    • 6.1 Pneumococcal Vaccines
    • 6.2 Polio Vaccines
    • 6.3 Varicella Vaccines
    • 6.4 Meningitis Vaccines
    • 6.5 Rotavirus Vaccines
    • 6.6 DTP Vaccines
    • 6.7 Measles, Mumps & Rubella (MMR) Vaccines
    • 6.8 Tuberculosis Vaccines
  • 7. Major Adult/Travel & Therapeutic Vaccines
    • 7.1 Hepatitis B Vaccines
    • 7.2 Malaria Vaccines
    • 7.3 Japanese Encephalitis Vaccines
    • 7.4 Ebola Vaccines
    • 7.5 Cervical Cancer Vaccines
    • 7.6 Typhoid Vaccines
    • 7.7 West Nile Vaccines
    • 7.8 HIV Vaccines
  • 8. Industry Analysis
    • 8.1 Market Drivers
      • 8.1.1 Diseases Prevention
      • 8.1.2 Higher Margins
      • 8.1.3 Increased Funding from Government & NGOs
      • 8.1.4 Government Regulations
      • 8.1.5 Blockbuster Potential of New Vaccines
      • 8.1.6 Increasing Population in Developing Countries
      • 8.1.7 Disease Awareness
    • 8.2 Opportunities
      • 8.2.1 Contract Research
      • 8.2.2 Influenza Vaccine Segment
      • 8.2.3 India & China - Future Hub for Pediatric Vaccine Manufacturing
      • 8.2.4 Cancer Vaccine Segment
      • 8.2.5 Addiction Vaccine Segment
    • 8.3 Challenges
      • 8.3.1 Huge R&D Cost
      • 8.3.2 Lack of Infrastructure for Trials & Manufactures
      • 8.3.3 Effective Vaccine Design
      • 8.3.4 Vaccine Supply
      • 8.3.5 Immunization Safety
  • 9. Vaccine Market Players
    • 9.1 Major Categories
      • 9.1.1 Vaccine Majors
      • 9.1.2 Vaccine-focused Biotech Companies
      • 9.1.3 Domestic-focused Vaccine Companies
    • 9.2 Key Players
      • 9.2.1 Sanofi-Aventis
      • 9.2.2 GlaxoSmithKline Plc.
      • 9.2.3 Merck & Co., Inc.
      • 9.2.4 Novartis
      • 9.2.5 Wyeth
  • List of Figures:
    • Figure 3-1: Vaccines Horizon (1960 to 2010)
    • Figure 4-1: Global - Vaccine Market (in Billion US$), 2003-2006E
    • Figure 4-2: Global - Forecast for Vaccine Market (in Billion US$), 2007-2010
    • Figure 5-1: Global - Vaccine Market Segmentation by Region (%), 2005
    • Figure 5-2: Global - Sales Split of Major Vaccine Manufacturers by Region (%), 2004
    • Figure 5-3: US - Vaccine Market (in Billion US$), 2003, 2006E, 2008E & 2013E
    • Figure 5-4: US - Pediatric Vaccine Market (in Billion US$), 2003, 2006E, 2008E & 2013E
    • Figure 5-5: US - Hepatitis Vaccine Market (in Million US$), 2003, 2006E, 2008E & 2013E
    • Figure 5-6: US - Biodefense Vaccine Market (in Million US$), 2003, 2006E, 2008E & 2013E
    • Figure 5-7: US - Influenza Vaccine Market (in Million US$), 2003, 2006E, 2008E & 2013E
    • Figure 5-8: US - Travel Vaccine Market (in Million US$), 2003, 2006E, 2008E & 2013E
    • Figure 5-9: US - Developmental Vaccine Market (in Million US$), 2008E & 2013E
    • Figure 5-10: Europe - Vaccine Market (in Billion US$), 2005, 2006E, 2008E & 2012E
    • Figure 5-11: Japan - Influenza Vaccine Production (in Million Units), 2001 & 2006E
    • Figure 5-12: China - Vaccine Market (in Million US$), 2005 & 2008-2010E
    • Figure 5-13: India - Vaccine Market (in Million US$) 2003, 2004, 2006E & 2008E
    • Figure 5-14: Global - Vaccine Market Revenue by Segment (in Billion US$), 2005, 2006E & 2010E
    • Figure 5-15: Global - Vaccine Market Share by Segment (%), 2005, 2006E & 2010E
    • Figure 5-16: Global - Basic Pediatrics Vaccine Market (in Billion US$), 2005 & 2006E
    • Figure 5-17: Global - Forecast for Basic Pediatrics Vaccine Market (in Billion US$), 2007-2010
    • Figure 5-18: Global - Enhanced Pediatrics Vaccine Market (in Billion US$), 2005 & 2006E
    • Figure 5-19: Global - Forecast for Enhanced Pediatrics Vaccine Market (in Billion US$), 2007-2010
    • Figure 5-20: Global - Proprietary Pediatrics Vaccine Market (in Billion US$), 2005 & 2006E
    • Figure 5-21: Global - Forecast for Proprietary Pediatrics Vaccine Market (in Billion US$), 2007-2010
    • Figure 5-22: Global - Adult/Travel Vaccine Market (in Billion US$), 2005 & 2006E
    • Figure 5-23: Global - Forecast for Adult/Travel Vaccine Market (in Billion US$), 2007-2010
    • Figure 5-24: Global - Therapeutics Vaccine Market (in Billion US$), 2005 & 2006E
    • Figure 5-25: Global - Forecast for Therapeutics Vaccine Market (in Billion US$), 2007-2010
    • Figure 5-26: Global - Cancer Vaccine Market (in Billion US$), 2005, 2008E & 2010E
    • Figure 5-27: Global - Addiction Vaccine Market (in Million US$), 2008E & 2010E
    • Figure 5-28: Global - Influenza Vaccine Market (in Billion US$), 2005 & 2006E
    • Figure 5-29: Global - Influenza Vaccine Market Share (%), 2004
    • Figure 5-30: Global - Forecast for Influenza Vaccine Market (in Billion US$), 2007-2010
    • Figure 6-1: Global - Pneumococcal Vaccine Market (in Billion US$), 2005 & 2010E
    • Figure 6-2: Global - Number of Polio Infection Incidences (2004-2006)
    • Figure 6-3: Global - Countries with Maximum Number of Polio Infection Incidences, 2006
    • Figure 6-4: Global - Polio Vaccine Market (in Million US$), 2004 & 2011E
    • Figure 6-5: Global - Inactivated Polio Vaccine Doses (in Million), 2006 & 2011E
    • Figure 6-6: Global - Meningitis Vaccine Market (in Billion US$), 2005 & 2010E
    • Figure 6-7: Global - Rotavirus Vaccine Market (in Billion US$), 2010E
    • Figure 6-8: Global - Number of Diphtheria Incidences by Region, 2005
    • Figure 6-9: Global - Number of Pertussis Incidences by Region, 2005
    • Figure 6-10: Global - Number of Tetanus Incidences by Region, 2005
    • Figure 6-11: Global - DTP Combos Market Share (%), 2004
    • Figure 6-12: Global - Number of Measles Incidences by Region, 2005
    • Figure 6-13: Global - Number of Mumps Incidences by Region, 2005
    • Figure 6-14: Global - Number of Rubella Incidences by Region, 2005
    • Figure 6-15: Global - Number of Tuberculosis Incidences (in Thousand), 2005
    • Figure 7-1: Global - Hepatitis B Surface Antigen Prevalence (%), 2005
    • Figure 7-2: Global - Hepatitis B Market (in Billion US$), 2006 & 2010E
    • Figure 8-1: Global - Profit Margins of Vaccines, Generics & Branded Drugs (%), 2006
    • Figure 8-2: Global - Sources of Financing for Vaccine Market (%), 2001
    • Figure 8-3: Global - Prevnar Vaccine Market (in Billion US$), 2003-2005
    • Figure 8-4: US - Drug Discovery Contract Research Organization Market (in Billion US$), 2006E & 2013E
    • Figure 8-5: Global - Confirmed Human Cases & Number of Deaths due to Avian Influenza A/ (H5N1), 2006
    • Figure 8-6: Global - Dose Consumption & Revenue by Income of Regions (%), 2005
    • Figure 9-1: Global - Vaccine Market Players (%), 2005
  • List of Tables:
    • Table 5-1: Global - Confirmed Human Cases & Number of Deaths due to Avian Influenza A/(H5N1) (2003-2006)
    • Table 7-1: Global - Number of HIV/AIDS Patients (in Million), 2006
    • Table 8-1: Global* - Vaccines Avert Deaths due to Diphtheria (in Thousand), 2001
    • Table 9-1: Global - Share of Vaccines in Total Pharma Sales of Major Players (%), 2005
    • Table 9-2: Global - Growth of Vaccines Segment of Major Pharma Players (%), 2005
    • Table 9-3: Global - Overall Growth of Major Pharma Players (%), 2005
    • Table 9-4: Global - Major Vaccine Companies (Segmentation by Revenue)
    • Table 9-5: Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
    • Table 9-6: GlaxoSmithKline Plc. - Key Financials (in Million US$), 2004-2006
    • Table 9-7: Merck & Co., Inc. - Key Financials (in US$), 2004-2006
    • Table 9-8: Novartis - Key Financials (in Million US$), 2004-2006
    • Table 9-9: Wyeth - Key Financials (in Million US$), 2004-2006